Abbott Laboratories (ABT) Liabilities and Shareholders Equity (2009 - 2026)

Abbott Laboratories has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $109.2 billion in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 30.02% year-over-year to $109.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $390.5 billion (up 21.58% YoY) and the FY2025 annual result came in at $86.7 billion, up 6.51% from the prior year.
• Liabilities and Shareholders Equity retreated to $109.2 billion in Q2 2026 per ABT's latest filing, from $110.4 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $110.4 billion in Q1 2026 and troughed at $22.3 billion in Q4 2022.
• A 5-year average of $77.4 billion and a median of $74.1 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity surged 227.77% in 2023, then fell 1.8% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $22.3 billion in 2022, then soared by 227.77% to $73.2 billion in 2023, then advanced by 11.2% to $81.4 billion in 2024, then increased by 6.51% to $86.7 billion in 2025, then gained by 25.95% to $109.2 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $109.2 billion, $110.4 billion, and $86.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.